Oesophageal Cancer Trial, Recruiting NCT05967910 Sponsor: Second Xiangya Hospital of Central South University Condition: Oesophageal Cancer
Back to Oesophageal Cancer

Oesophageal Cancer Trial, Recruiting

NCT05967910
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 to 75 years old
  • People who have been diagnosed with esophageal cancer confirmed by laboratory tissue testing
  • People for whom tumor tissue samples can be collected
  • People who have at least one measurable area of cancer that can be tracked using standard imaging guidelines
  • People who have not yet received any systemic (whole-body) treatment for advanced or metastatic esophageal cancer — meaning this would be their first such treatment
  • People whose heart function and electrical activity appear normal on an ECG (heart tracing)
  • People whose blood counts and liver and kidney function results fall within the required ranges

Who may not be able to join:

  • People who have another separate cancer diagnosis at the same time
  • People who have been taking steroid hormones or immune-suppressing medications long-term
  • People who have an ongoing acute or chronic mental health condition
  • People who are currently taking, or have taken long-term, medications that affect the sympathetic nervous system (the part of the nervous system that controls automatic body responses such as heart rate) (confirm with trial site)
  • People who have another cancer that currently requires systemic (whole-body) treatment
  • People who have previously taken part in another clinical drug trial
  • People who have brain metastases (cancer that has spread to the brain) that are causing symptoms

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +86 135744858332

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Second Xiangya Hospital of Central South University
Registry
ClinicalTrials.gov
Start date
1 May 2023
Est. completion
1 May 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Objective Response Rate (ORR); Progression-free survival (PFS); Effect of Chronic stress on efficacy of immune checkpoint inhibitors

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov